A chitosan/dextran-based hydrogel as a delivery vehicle of human bone-marrow derived mesenchymal stem cells. (7th June 2017)

• Record Type: Journal Article
• Authors: Nelson, Vicky J; Dinnunhan, M F K; Turner, Paul R; Faed, Jim M; Cabral, Jaydee D
• Is Part Of: Biomedical materials. Volume 12:Number 3(2017:Jun.)
• Publication Date: 2017-06-07
• Subjects: chitosan -- dextran aldehyde -- hydrogel -- mesenchymal stem cells -- regenerative medicine; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1088/1748-605X/aa70f2
• Languages: English
• ISSNs: 1748-6041

Abstract

Abstract: A chitosan/dextran-based (CD) injectable, surgical hydrogel has been developed and shown to be an effective post-operative aid in prevention of scar tissue formation in vivo . The CD hydrogel's effectiveness in a surgical setting prompted an investigation into its capacity as a potential delivery vehicle for bone marrow derived mesenchymal stem cells (BM-MSCs) for regenerative wound healing applications. By housing BM-MSCs within a biocompatible, injectable, hydrogel matrix, viability and protection in cultivation, as well as direct delivery to the damaged site in the host tissue may be achieved. In vitro BM-MSC cell viability in the presence of CD hydrogel was determined by LIVE/DEAD ® fluoresence staining. Flow cytometry studies revealed expression of a conventional BM-MSC surface marker profile. A colony forming cell assay showed a slight statistically significant decrease in the number of colonies grown in CD hydrogel as compared to control cells. In addition, BM-MSCs in the CD hydrogel were able to successfully differentiate into adipocytes and osteocytes. In summary, the CD hydrogel supports MSC growth and differentiation; and therefore, may be used as a potential stem cell delivery vehicle for regenerative medicine and tissue engineering applications.